8-K: GoodRx Reports Fourth Quarter and Full Year 2024 Results, Meeting Expectations

GoodRx's Q4 and full-year 2024 results align with previous guidance, showcasing revenue growth and improved profitability.

Summary

• GoodRx has released its financial results for Q4 and the full year 2024.
• Q4 revenue reached $198.6 million, with a net income of $6.7 million and an adjusted EBITDA of $67.1 million.
• For the full year, revenue was $792.3 million, net income was $16.4 million, and adjusted EBITDA was $260.2 million.
• The company exited the quarter with over 7 million consumers of prescription-related offerings.
• Revenue increased by 6% year-over-year, driven by prescription transactions and pharma manufacturer solutions.
• Subscription revenue decreased by 8% due to the sunset of the Kroger Savings Club partnership.
• GoodRx anticipates revenue between $810 million and $840 million for the full year 2025, with adjusted EBITDA between $270 million and $286 million.
• The company is focused on investing for profitable growth, paying down debt, buying back shares, and strategic M&A.

Sentiment

Score: 7

Explanation: The report presents a positive outlook with revenue growth and improved profitability, but also acknowledges existing risks and challenges. The sentiment is cautiously optimistic.

Positives

• Revenue increased by 6% to $792.3 million for the full year 2024.
• Net income improved to $16.4 million compared to a net loss of $8.9 million in the previous year.
• Adjusted EBITDA increased to $260.2 million, up from $217.4 million.
• Pharma manufacturer solutions revenue saw a significant increase of 26% to $107.2 million.
• Net cash provided by operating activities increased to $183.9 million from $138.3 million.

Negatives

• Subscription revenue decreased by 8% to $86.5 million due to the sunset of the Kroger Savings Club partnership.
• The sunset of the Kroger Savings Club impacted subscription revenue, contributing $1.1 million in 2024 compared to $9.0 million in 2023.

Risks

• The company acknowledges risks related to changes in medication pricing and reliance on a limited number of industry participants.
• Forward-looking statements are subject to various risks and uncertainties, including those related to market competition, regulatory changes, and economic factors.
• The company's ability to maintain positive perception of its platform and brand is crucial for continued growth.

Future Outlook

GoodRx anticipates revenue between $810 million and $840 million for the full year 2025, with adjusted EBITDA between $270 million and $286 million.

Management Comments

• Wendy Barnes, CEO, is excited to join GoodRx at a pivotal time and help accelerate its ability to solve consumer pain points in getting medication.
• Chris McGinnis, CFO, believes GoodRx is poised to leverage its core capabilities and enhance access to medications at affordable prices.
• McGinnis stated that the company made solid progress in 2024, exemplified by the year-over-year growth in profitability and significant operating cash flows.

Industry Context

GoodRx operates in the competitive prescription savings market, connecting consumers, healthcare professionals, and pharmacies to facilitate affordable medication access. The company's growth in pharma manufacturer solutions reflects a broader trend of pharmaceutical companies seeking direct engagement with consumers.

Comparison to Industry Standards

• GoodRx's adjusted EBITDA margin of 32.8% is competitive with other established players in the healthcare technology space.
• Companies like Teladoc Health and Amwell, while operating in different segments of telehealth, also focus on improving access to healthcare services, but their financial metrics and business models differ significantly.
• Compared to traditional pharmacy benefit managers (PBMs), GoodRx offers a more transparent pricing model, directly benefiting consumers.

Stakeholder Impact

• Shareholders can expect continued focus on profitable growth and shareholder value creation.
• Consumers will benefit from GoodRx's efforts to enhance access to affordable medications.
• The company's relationships with pharmacies and pharma manufacturers are expected to deepen, creating a more efficient healthcare ecosystem.

Next Steps

• GoodRx management will host a conference call and webcast on February 27, 2025, to discuss the results and the company's business outlook.
• The company intends to continue investing for profitable growth, paying down debt, buying back shares, and pursuing strategic M&A.

Key Dates